SECONDSIGHT

Filed pursuant to Rule 433 Dated April 29, 2020 Issuer Free Writing Prospectus supplementing the Preliminary Prospectus Supplement dated April 29, 2020 and the Prospectus dated November 9, 2017 Registration No. 333-221228

Second Sight Medical Products, Inc. (NASDAQ: EYES)

Discover Life in a New Light®

Investor Presentation



Forward Looking Statements Free Writing Prospectus

- The following slides and any accompanying and presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be carered by the "sofe herbor" created by these sections. All statements in this release that are not besed an historical fact are "farward looking statements." These statements may be identified by words such as "estimates," "anticipates," "projects," "plans" ar "planned," ristrategy," "goal," "soeks," "may," "will," "expects," "intends," "belows," "shaukl," and similar expressions, or the negative versions thereof, and which also may be identified by their context. All statements that address operating performance or events ar developments that Second Sight expects or anticipates will occur in the future, such as stated objectives ar goals, ar the information on which such expectations were based any change. Farward-looking statements include in this release an its current expectations, the information on which such expectations were based may change. Farward-looking statements include in the relations described in this release and in Management's and sing these risks and uncertainties which cauld cause actual results to differ materially far these or interactions are to be address of a statements included in this release on its current expectations, the information on which such expectations were based may change. Farward-looking statements include in the factor in management's based any farward-looking statements include in the reports field from time to time with the Securities and Exchange Cammission. We urge you to consider these risks and uncertainties described in the Risk Factors and in Management's becausing and Analysis of Fine acid Candition and Results of Operations sections of aur Annual Report, on farm 10-K, filed on March 19, 2020 and aur other reports filed from time to time with the Securities and Exchange Cammission. We urge you to
- Second Sight Medical Products, Inc. has filed a registration statement (including the prospectus supplement and the accompanying prospectus) with the Securities and Exchange Commission (the "SEC") with respect to the affering of shares of the Company's common stack to which this communication relates. Before you invest, you should read the prospectus supplement and the accompanying prospectus in the registration statement (Registration No. 333-221228) and the after documents Second Sight Medical Products, Inc. has filed with the SEC and incorporated by reference for more complete information about Second Sight Medical Products, Inc. and this affering. You may get these documents for free by visiting EDGAR on the SEC website at http://sec.gov. Capies of the prospectus supplement and eccompanying prospectus may also be obtained from ThinkEquity, a division of Fordham Financial Management, Inc., Prospectus Department, 17 State Street, 22nd Ficar New York NY 10004, telephane (877) 436-3673, email: prospectus@athink-equity.com
- This communication should be read in conjunction with the Preliminary Prospectus Supplement and the accompanying prospectus. The information in this communication supersedes the
 information in the Preliminary Prospectus Supplement and the accompanying prospectus to the extent inconsistent with the information in the Preliminary Prospectus Supplement and the
 accompanying prospectus.

Highlights

SECONDSIGHT



Second Sight is the Global Leader in Artificial Vision

- 1^{s1} FDA approved retinal prosthesis
- Partnered with 20 premier hospitals in the U.S. to build regional artificial vision centers Centers of Excellence Model
- Effective patient outreach and screening competencies over 1,000 potential patients in current database

Leaders in market access and reimbursement

- O Argus II is an established therapy in over a dozen markets globally; over 300 implants to date
- Achieved highest CMS outpatient reimbursement rate for a device and related procedure in U.S. at \$152,500 for 2019
- O CMS' efforts to provide reimbursement for Breakthrough Devices on approval apply to Orion


Orion leverages Argus II technology platform

- Established technology with 10+ years proven implant durability
- Proprietary algorithms for artificial vision
- Over 85 issued U.S. patents for Orion, over 300 patents in total with 40 pending applications

What is Orion?

SECONDSIGHT

4



How Orion Technology Works? https://youtu.be/bty9owi6s9c

Orion Patient Stories



ABC 6 Philadelphia https://6abs.com/health/brain-implant-gives-blind-new-way-to-see-worldaround-them/5553255/



CNET What the Future: Artificial Vision for the Blind https://www.cnet.com/videos/this-machine-creates-artificial-visionfor-the-blind/



The Story of Medtech https://thestoryofmedtech.org/story/seeingonew-artificial-vision-richards-story

Orion [®] Has the Potential to Treat Virtually All Forms of Blindness

SECONDSIGHT

Initial target population in US represents a \$1 billion plus market opportunity¹



Orion [®] Market Potential Grows Significantly In Future Years

SECONDSIGHT



Includes retinitis pigmentosa, glaucoma, diabetic retinopathy, optic nerve disease, eye trauma


Based on company estimates and 3st party market research
 Worldwide addressable market estimated based on total population and extrapolated from US market research.
 Growth from label expansion into better visioned patients assumes 4x growth by treating hand mation and lingui

Ongoing six subject Early Feasibility Study at UCLA Medical Conter and Baylor

Safety	Square Localization (SL)	Direction of Motion (DOM)	FLORA	
1 SAE (seizure) 6 AEs (2 subjects, 4* subjects with no AEs)	5 of 6 Perform Better with Orion System ON versus OFF	6 of 6 Perform Better with Orion System ON versus OFF	5 of 6 Receive Benefit from Orion System while Performing Daily Tasks	
Observations from rehable	and a set of the set o		1. 12 W 1/2W 1/200	
	essions indicate subjects can perfor	m tasks with Orion that they could	not do without	
Examples include:	ssions indicate subjects can perfor	m tasks with Orion that they could	not do without	
		m tasks with Orion that they could	not do without	
Examples include: O Locate people in front o			not do without	
Examples include: Cocate people in front o Walk down sidewalk in	f them		not do without	
Examples include: Cocate people in front o Walk down sidewalk in	f them dependently and identify parked cars and d riped balls on a pool table		not do without	

*Four subjects not experiencing any device- or procedure-related AEs as of June 17, 2019 IM SM adjudication meeting

Orion US Reimbursement Strategy



Orion Regulatory Pathway — PMA

KEY MILESTONES TO COMMERCIALIZATION							
 FLORA-20 validation 	 FDA agreement on pivotal trial design Submit IDE for Orion II 	 IDE approval 1^{er} Orion II implant in pivotal trial 	Last Orion II implant in pivotal trial	 Study follow-up period (12 months post- implant) Interim study results available 	PMA submission	PMA approval Commercialization	

Partnering with Other Firms to Develop and Integrate Assistive Technologies with Orion

SECONDSIGHT



Allow users to filter out objects further

view in conjunction with the

Research projects to drive potential benefit for Orion users

SECONDSIGHT

Capitalization Table Pre-Offering

	Common Shares Outstanding	15,657,700	
	Warrants (WAEP ¹ \$11.76)	7,682,244	
÷	Options (WAEP \$18.82)	566,079	

¹ One class of warrants outstanding at exercise price of \$11.76. Listed as EYESW

Second Sight Investment Highlights

SECONDSIGHT

Orion represents a multi-billion dollar apportunity

- 🕐 Potential to treat nearly all forms of blindness including retinitis pigmentosa, diabetic retinopathy, glaucoma, optic nerve disease and eye injury
- O Six subject feasibility study at UCLA and Baylor has positive results that support advancement

Orion leverages Argus® II technological backbone and is designated a Breakthrough Device by FDA

- 🧿 Orion leverages Argus technology including implantable array, externals and proprietary software / algorithms for creating artificial vision
- FDA Breakthrough Device designation provides expedited regulatory and clinical pathway

Future technologies enhance or improve artificial vision experience

- O Different array designs including a higher electrode count array and the associated electronics
- Pertracking, thermal imaging, depth-based decluttering and object and/or recognition facial recognition provide improved or more useful vision

Large U.S. patient database and proven reimbursement and market access capabilities

- O Demonstrated patient outreach and screening expertise with over 1,000 potential Orion patients in a growing U.S. database
- Orion will benefit from company's efforts to secure an Argus II reimbursement rate of \$152,500 in U.S. as well as CMS initiatives to establish reimbursement for FDA Breakthrough Devices upon regulatory approval.

Contacts

SECONDSIGHT

Socoad Sight Madical Products, Inc.

12744 San Fernando Road Suite 400 Sylmar, CA 91342 Main: 818-833-5000 www.secondsight.com

John Blake CFO jblake@secondsight.com

Retail Investor Relations

Greg Falesnik Managing Director MZ North America Direct: 949-385-6449 Greg.Falesnik@mzgroup.us

Institutional Investor Relations

Lisa Wilson President In-Site Communications, Inc. Direct: 212-452-2793 <u>lwilson@insitecony.com</u>